Immune-mediated focal segmental glomerulosclerosis (FSGS)

Clinical trials for Immune-mediated focal segmental glomerulosclerosis (FSGS) explained in plain language.

Never miss a new study

Get alerted when new Immune-mediated focal segmental glomerulosclerosis (FSGS) trials appear

Sign up with your email to follow new studies for Immune-mediated focal segmental glomerulosclerosis (FSGS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug VIS171 enters human trials for lupus, hair loss, and kidney disease

Disease control Ongoing

This early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care,…

Matched conditions: IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Phase 1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control

Last updated Jul 24, 2026 00:00 UTC

Immune-mediated focal segmental glomerulosclerosis (FSGS)

Get alerted when new Immune-mediated focal segmental glomerulosclerosis (FSGS) trials appear

New drug VIS171 enters human trials for lupus, hair loss, and kidney disease